ReviewJournal of translational medicine2017
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
Review in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 27 citations in OpenAlex.
- A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.Journal of translational medicine · 2023Article
- Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Immunostimulatory biomaterials to boost tumor immunogenicity.Biomaterials science · 2020Review
- Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020Review
- The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.Oncotarget · 2019Article
- Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells.Frontiers in immunology · 2019Review
- Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?Vaccines · 2018Review
- Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.Cancer immunology, immunotherapy : CII · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy consists of activating the patient's immune system to fight cancer and has the great potential of preventing future relapses thanks to immunological memory. A great variety of strategies have emerged to harness the immune system against tumors, from the administration of immunomodulatory agents that activate immune cells, to therapeutic vaccines or infusion of previously activated cancer-specific T cells. However, despite great recent progress many difficulties still remain, which prevent the widespread use of immunotherapy. Some of these limitations include: systemic toxicity, weak immune cellular responses or persistence over time and most ultimately costly and time-consuming procedures. MAIN BODY: Synthetic and natural biomaterials hold great potential to address these hurdles providing biocompatible systems capable of targeted local delivery, co-delivery, and controlled and/or sustained release. In this review we discuss some of the bioengineered solutions and approaches developed so far and how biomaterials can be further implemented to help and shape the future of cancer immunotherapy.
conclusionThe bioengineering strategies here presented constitute a powerful toolkit to develop safe and successful novel cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.